A rapid high-performance liquid chromatographic (HPLC) method using a monolithic column has been developed for determination of valsartan in human plasma. The assay is based on protein precipitation using acetonitrile and fluorescence detection. The assay enables the measurement of valsartan for therapeutic drug monitoring with a minimum quantification limit of 20 ngml -1 . The method involves simple, one-step extraction procedure and analytical recovery was nearly complete. The separation was carried out in reversed-phase conditions using a Chromolith Performance (RP-18e, 100×4.6 mm) column with an isocratic mobile phase consisting of 0.01 M disodium hydrogen phosphate buffer-acetonitrile (60:40 v/v) adjusted to pH 3.5 with diluted phosphoric acid. The excitation and emission wavelengths were set at 230 and 295 nm, respectively. The calibration curve was linear over the concentration range 20-2000 ngml -1 . The coefficients of variation for inter-day and intra-day assay were found to be less than 6%. The assay was applied for the analysis of blood samples from a pharmacokinetic study. 
Introduction
Valsartan is a potent and specific competitive angiotensin II antagonist which is used in the management of hypertension. Valsartan is rapidly absorbed following oral administration, with a rather poor bioavailability of about 23%. Peak plasma concentrations of valsartan occur 2 to 4 hours after ingestion. The drug is not significantly metabolized and is excreted mainly via the bile as unchanged drug [1, 2] . Several high-performance liquid chromatographic (HPLC) methods are available for determination of valsartan in plasma. All published assays employ native fluorescence of valsartan and use fluorimetric detection [3] [4] [5] [6] [7] [8] [9] [10] . The sample preparation involves either liquid-liquid extraction with methyl-tert-butyl ether [3] and ethyl acetate [4] or solid-phase extraction using C8 [6] [7] [8] or cyclohexyl [3, 8] cartridges. The limit of quantification (LOQ) in these procedures is 5-130 ngml -1 , run times are typically 10-30 min. Macek et al [10] reported a rapid HPLC/fluorescence method for analysis of valsartan in human plasma. However, this method had low sensitivity (LOQ = 100 ngml -1 ) and internal standard was not used. Accordingly, available pharmacokinetic profiles were only provided for the higher dose (160 or 320 mg) subjects. Recently, a LC-MS/MS method has been reported for the analyses of valsartan in human plasma by Koseki et al [11] . This method is highly selective and very sensitive, with low LOQ of 2 ngml -1 . However, this method is not practicable for most laboratories because of its special analytical requirements and financial reasons. Moreover, some purification steps are necessay before the samples are injected into chromatographic system such as liquid-liquid extraction, solid phase extraction, etc. Monolithic silica columns as stationary phases exhibit a tailor-made bimodal pore structure with both macropores or through pores and mesopores. The most unique feature of these columns is their high permeability, which is nearly twice as high as that of packed columns. As a result of their high permeability monolithic silica columns are especially suitable for high throughput analysis. This is typically needed in pharmacokinetic studies where the decreasing concentration of a given drug is monitored [12] . As opposed to individual particles packed into chromatographic columns, monolithic supports are cast as continuous homogenous phases. They represent an approach that provides high rates of mass transfer at lower pressure drops as well as high efficiencies even at elevated flow rates. Therefore, much faster separations are possible and the productivity of chromatographic processes can be increased by at least one order of magnitude as compared to traditional chromatographic columns packed with porous particles. This enhances the speed of the separation process and reduces backpressure and unspecific binding without sacrificing resolution [13] . This study described a fast HPLC method using a monolithic column with fluorescence detection, which enabled the determination of valsartan with good accuracy at low drug concentrations in plasma using singlestep extraction procedure. The sample preparation only involved protein precipitation and no evaporation step was required. Also, the use of a smaller sample volume provided an advantage as compared with some previous methods [3, 6] that required large sample volume for analysis of valsartan. The overall time of analysis has been improved by the elimination of tedious extraction steps and optimization of chromatographic conditions using monolithic column (run time < 6 min).We also demonstrated the applicability of this method for pharmacokinetic studies in humans.
Material and methods
Chemicals
Valsartan and ranitidine (internal standard), were supplied by Osveh other chemicals were obtained from Merck (Darmstadt, Germany). Water was obtained by double distillation and purified additionally with a Milli-Q system.
Instruments and chromatographic conditions
The 
Sample preparation
To 450 μl of plasma in a glass-stoppered 5 ml centrifuge tube were added 50 μl of atorvastatin as internal standard (12 μgml -1 ) and 500 μl of acetonitrile. After mixing (30 s), the mixture was centrifuged for 10 min at 8000 rpm. Finally 20 μl of supernatant was injected into the liquid chromatograph.
Biological samples
24 male healthy volunteers were included in this study. 
Stability
The stability of valsartan was assessed for two sets of spiked plasma samples (with a low and high concentration) stored at −20 °C for up to two months and at ambient temperature for at least 24 h. The stability of stock solutions stored at −20 °C and ambient temperature were determined by injecting appropriate dilutions of stocks in methanol and comparing their peak areas with fresh stocks prepared on the day of analysis. Samples were considered to be stable, if the assay values were within the acceptable limits of accuracy and precision.
Plasma standard curve
Blank plasma was prepared from heparinized whole-blood samples collected from healthy volunteers and stored at -20 °C. After thawing, stock solution of valsartan was added to give final concentrations of 20, 50, 100, 250, 500, 1000, 1500 and 2000 ng ml -1 . Internal standard solution was added to each of these samples to yield a concentration of 600 ng ml -1 . The samples were then prepared for analysis as described above.
Precision and accuracy
The precision and accuracy of the method were examined by adding known amounts of valsartan to pooled plasma (quality control samples). For intra-day precision and accuracy five replicate quality control samples at each concentration were assayed on the same day. The inter-day precision and accuracy were evaluated on three different days.
Limit of quantification (LOQ) and recovery
For the concentration to be accepted as LOQ, the percent deviation from the nominal concentration (accuracy) and the relative standard deviation must be ±10% and less than 10%, respectively, considering at least five-times the response compared to the blank response. The relative analytical recovery for plasma at three different concentrations of valsartan (100, 800 and 2000 ng ml -1 ) was determined. Known amounts of valsartan were added to drug-free plasma and the internal standard was then added. The relative recovery of valsartan was calculated by comparing the peak areas for extracted valsartan from spiked plasma and a standard solution of valsartan in methanol containing internal standard with the same initial concentration (six samples for each concentration level).
Selectivity and specificity
Control human plasma, obtained from 24 healthy volunteers, was assessed by the procedure as described above and compared with respective plasma samples to evaluate selectivity of the method. Losartan, Sotalol, atenolol, carvedilol,
lovastatin and hydrochlorthiazide were also tested for potential interferences.
Pharmacokinetic Analysis
Valsartan pharmacokinetic parameters were determined by non (Table 1) . 0.0120±0.0007
The limit of quantification (LOQ), as previously defined, was 20 ngml -1 for valsartan. This is sensitive enough for drug monitoring and pharmacokinetic studies. We assessed the precision of the method by repeated analysis of plasma specimens containing known concentrations of valsartan. As shown in Table 2 , coefficients of variation were less than 6%, which is acceptable for the routine measurement of valsartan. The relative analytical recovery for plasma at three different concentrations of valsartan was determined. The average recovery was 96.3± 1.3%. Stability was determined for spiked plasma samples under the conditions as previously described. The results showed that the samples were stable during the mentioned conditions (Table 3) . The aim of our study was to develop a rapid and sensitive method for the Table 4 . These pharmacokinetic parameters were in accordance with those found previously [3, 5] . T max (h) C max (ng mL -1 ) 
